Personalized Neural Stem Cell Therapy
Precision Treatment for Parkinson's Disease
Led by world-renowned scientists and clinicians, we develop and advance cell replacement therapy utilizing our proprietary autologous stem cells approach to treat Parkinson’s disease and other degenerative CNS aliments.
One of the Most Debilitating Diseases
One of the most common chronic neurodegenerative diseases in the elderly. It affects one of every 100 persons over the age of 60 and up to 10 million patients worldwide.
Autologous Stem Cells
Targeted , Personalized Cell Replacement Therapy
Not all stem cells are created equal. Our technology harvests a patient's own adult stem cells. After in vitro expansion, differentiation and characterization, the stem cells are then re-implanted back to the patient to provide the most effective and safe therapeutics.
Neurogeneration's proprietary adult human stem cell technology regenerates healthy neural tissue similar to that found at birth. During the process of recreating a large number of unaltered primitive neural cells in vitro, Neurogeneration scientists can replicate the pathways of development and cell maturation that lead to the reformation of healthy neural circuitry.
1. Using a safe small surgical procedure , a small tissue sample is harvested from a patient’s brain.
2. The tissue is then placed into cell cultures and through precise expansion, differentiation and characterization steps, the final product containing dopamine secreting neuron stem cells and other vital cells are ready to be re-implanted to treat patients.
3. Stem cells are injected back to the patient through a minimally invasive micro-injection.
Phase I clinical result
Safety: Using a patient's own cells for treatment steers away from possible immunogenetic reactions and potential ethnic concerns. The procedures are very similar to the current widely-adopted DBS surgeries--the harvesting of the cells and the micro-infusion procedure have been well-established and are considered very safe
Effectiveness: Our technology has shown that our stem cells have a high survival rate and can be successfully intergrated into patients' brain circuitry resulting significant improvement in patients' conditions in our Phase I clinical trials
Michel Levesque, MD
CEO & Founder
Mohamedi Kagalwala, PhD
Patricia Eastman, MHA
Scientific advisory board
Kalpana Merchant, PhD
Former CSO, Eli Lilly Translational Science
PhD, Neuropharmacology University of Utah
Eliezer Masliah, MD, PhD
Tenured Professor, Neurosciences and Pathology, UCSD
Director, Laboratory of Experimental Neuropathology
David Brafman, PhD
PI, UCSD Sanford Consortium for Regenerative Medicine
Karl Willert, PhD
Core Director, UCSD stem cell Program
Associate Professor, UCSD
Alysson Muotri, PhD
Associate Director, UCSD stem cell Program
Associate Professor, UCSD